Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H15N3O.CH4O3S |
| Molecular Weight | 349.405 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(O)(=O)=O.CC1=CN(C(C)=N1)C2=CC3=C(NC(=O)C=C3)C(C)=C2
InChI
InChIKey=OZIIHULZOTWACX-UHFFFAOYSA-N
InChI=1S/C15H15N3O.CH4O3S/c1-9-6-13(18-8-10(2)16-11(18)3)7-12-4-5-14(19)17-15(9)12;1-5(2,3)4/h4-8H,1-3H3,(H,17,19);1H3,(H,2,3,4)
Nanterinone [UK 61260], a phosphodiesterase III inhibitor, was undergoing II evaluation with Pfizer in the US for the treatment of heart failure. Nanterinone is a positive inotropic and balanced-type vasodilating drug, only partially based on phosphodiesterase III inhibition. Preliminary data from controlled studies suggest satisfactory long-term efficacy and safety.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Characterization of the arteritis induced by infusion of rats with UK-61,260, an inodilator, for 24 h. A comparison with the arteritis induced by fenoldopam mesylate. | 1995 |
|
| 2(1H)-quinolinones with cardiac stimulant activity. 3. Synthesis and biological properties of 6-imidazol-1-yl derivatives. | 1989-07 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID30145514
Created by
admin on Mon Mar 31 18:11:19 GMT 2025 , Edited by admin on Mon Mar 31 18:11:19 GMT 2025
|
PRIMARY | |||
|
92089
Created by
admin on Mon Mar 31 18:11:19 GMT 2025 , Edited by admin on Mon Mar 31 18:11:19 GMT 2025
|
PRIMARY | |||
|
O345A477QI
Created by
admin on Mon Mar 31 18:11:19 GMT 2025 , Edited by admin on Mon Mar 31 18:11:19 GMT 2025
|
PRIMARY | |||
|
102791-74-2
Created by
admin on Mon Mar 31 18:11:19 GMT 2025 , Edited by admin on Mon Mar 31 18:11:19 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
